<SEC-DOCUMENT>0001937653-24-000049.txt : 20241031
<SEC-HEADER>0001937653-24-000049.hdr.sgml : 20241031
<ACCEPTANCE-DATETIME>20241031161107
ACCESSION NUMBER:		0001937653-24-000049
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241031
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241031
DATE AS OF CHANGE:		20241031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Inc.
		CENTRAL INDEX KEY:			0001937653
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41535
		FILM NUMBER:		241415328

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		302-274-8744

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zymeworks Delaware Inc.
		DATE OF NAME CHANGE:	20220712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zyme-20241031.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:457b11c3-c8ff-41d3-9bb5-ed20e848ffe8,g:a9be2a4a-fbbc-4261-b028-b0c2d94038e1,d:e42f6cd917c4439ebab0f0a8f629a484-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zyme-20241031</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-23">0001937653</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-24">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zyme-20241031.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-31</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie42f6cd917c4439ebab0f0a8f629a484_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;padding-left:170.2pt;padding-right:170.2pt;text-align:center"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934 </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October&#160;31, 2024</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Zymeworks Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:32.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.926%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.928%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-41535</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">88-3099146</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></td><td colspan="6" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">108 Patriot Drive, Suite A</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Middletown</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">19709</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">302</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">274-8744</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:2.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:40.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.618%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.00001 par value per share</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ZYME</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;2.02</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESULTS OF OPERATIONS AND FINANCIAL CONDITION</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-21">October&#160;31, 2024</ix:nonNumeric>, Zymeworks Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the  three and nine months ended September&#160;30, 2024. A copy of the press release is attached as Exhibit&#160;99.1 to&#160;this&#160;Current Report on Form&#160;8-K (this &#8220;Form 8-K&#8221;). </span></div><div style="margin-top:12pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;7.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGULATION FD DISCLOSURES</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#8217;s website (www.zymeworks.com), its investor relations website (ir.zymeworks.com), its news site (ir.zymeworks.com/press-releases), its publications site (zymeworks.com/publications) and its events and presentations site (ir.zymeworks.com/events-and-presentations). The Company uses these channels, as well as social media, including its X account (@ZymeworksInc) and LinkedIn account (www.linkedin.com/company/zymeworks), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</span></div><div style="margin-top:12pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.202%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND EXHIBITS</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) Exhibits </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"/><td style="width:18.998%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="exhibit991q3_2024xpressxre.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="exhibit991q3_2024xpressxre.htm">October 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline" href="exhibit991q3_2024xpressxre.htm">1, 2024</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cover Page Interactive Data File (embedded as Inline XBRL document)</span></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under Items 2.02 and 7.01 of this Current Report on Form&#160;8-K&#160;and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="margin-bottom:8pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.064%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ZYMEWORKS INC.</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:42.287%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.770%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.290%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-22">October&#160;31, 2024</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leone Patterson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leone Patterson</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Business Officer and Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991q3_2024xpressxre.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6b7d61cbef94495dbca3cb508ca4facd_1"></div><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><img alt="zw_logo.jpg" src="zw_logo.jpg" style="height:125px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Zymeworks Provides Corporate Update and<br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reports Third Quarter 2024 Financial Results </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conference</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Our partner Jazz Pharmaceuticals presented new and updated clinical data at ESMO 2024  on zanidatamab highlighting its potential for the treatment of multiple HER2-positive (HER+) indications</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Zymeworks to host in-person and virtual R&#38;D day in New York City on December 12, 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">The Company has completed the initial $30 million of its Share Repurchase Program for 2,545,402 shares at an average price per share of $11.79 a</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">s of October 31,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> 2024.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.15pt">Reported $374.9 million in cash resources as of September&#160;30, 2024, which when combined with certain anticipated </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">regulatory milestone payments provides a projected cash runway into 2H 2027</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Will host conference call with management today at 4&#58;30 p.m. Eastern Time (ET)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Vancouver, British Columbia (October&#160;31, 2024) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211; Zymeworks Inc. (Nasdaq&#58; ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported financial results for the</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> three and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> months ended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> September&#160;30, 2024 and provided a summary of recent business highlights.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;2024 has been a pivotal year for us so far, marking several significant firsts across our pipeline. Our partner Jazz Pharmaceuticals has submitted a New Drug Application for zanidatamab, the late-stage HER2-targeting bispecific antibody to the FDA and we eagerly anticipate the potential for its first United States approval in second-line biliary tract cancer, with an assigned action date of November 29. This would be an important achievement not only for us and our partners Jazz and BeiGene, but for BTC patients with limited treatment options,&#8221; said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. &#8220;In parallel, we&#8217;ve dosed the first patient in our global Phase 1 study for our first bispecific T cell engager, ZW171.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Mr. Galbraith continued, &#8220;We believe that the novel design for our nominated candidates represents the next wave of innovation in oncology. As we continue to advance these early-stage assets into the clinic, we are also strategically expanding our focus on new modalities and therapeutic areas within our next generation of R&#38;D candidates, broadly in solid tumors, hematologic cancers and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">autoimmune and inflammatory diseases. Later this year, we look forward to sharing more about these next-generation of antibody-drug conjugates and multi-specific antibodies which leverage our technology platforms to target multiple disease pathways. We believe this approach will be key to continue driving the long-term growth of our R&#38;D pipeline and delivering transformative therapies to patients worldwide.&#8221;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:105%">Recent Highlights and Current Developments</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:105%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;padding-left:14.15pt">The Company will host an in-person and virtual R&#38;D day in New York, NY on December 12, 2024. A live webcast of the event will be available via the Investor section of our company website and will begin at 8&#58;30 am Eastern Time. As part of the event, we will feature in-depth presentations including&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;padding-left:14.11pt">Updates on our portfolio of solid tumor targeting antibody-drug conjugates (ADCs) and T-cell engager (TCE) molecules, featuring key opinion leaders from these therapeutic areas who will join the Company&#8217;s management team to discuss ongoing R&#38;D and clinical activities&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;padding-left:14.11pt">Candidate nomination from our Trispecific TCE platform as the last product candidate selected in our '5 by 5' R&#38;D strategy&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;padding-left:14.11pt">Strategy and rationale for expansion into new therapeutic areas in hematological cancers and autoimmune and inflammatory diseases and preclinical development progress on potential investigational new drug (IND) applications for multiple new product candidates in 2026 and beyond.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:105%">Progression of Wholly-Owned Research &#38; Development Programs</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In October 2024, we announced that the first patient has been dosed in the first-in-human Phase 1 trial (NCT06523803) to evaluate the safety and tolerability of the investigational therapy ZW171 in the treatment of advanced or metastatic ovarian cancer, non-small cell lung cancer (NSCLC), and other MSLN-expressing cancers. The Phase 1 study is a two-part, o</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">pen-label, multi-center study that is expected to enroll approximately 160 adult patients with advanced MSLN-expressing cancers. Part 1 of the study will evaluate the safety and tolerability of ZW171 and involve dose escalation in patients with advanced ovarian and NSCLC, with secondary endpoints assessing pharmacokinetics and confirmed objective response rate. Part 2 of the study will involve dose expansion in three cohorts (ovarian cancer, NSCLC, and a basket cohort enrolling patients with any MSLN-expression) and will evaluate the anti-tumor activity of ZW171, with primary endpoints focused on safety and tolerability and secondary endpoints assessing progression-free survival (PFS), duration of response (DoR) rates, and overall survival. The Company expects to conduct the Phase 1 study at investigator sites in North America, Europe, and the Asia-Pacific region.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">The Company is actively recruiting patients in the global Phase 1, open-label, multicenter study of ZW191 (NCT06555744). The study aims to enroll 145 participants with advanced solid tumors across North America, Europe, and the Asia-Pacific region. The study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ascending doses of ZW191.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">In October 2024, Zymeworks presented preclinical data at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (ENA) Conference on two ADC product candidates, ZW220 and ZW251, both of which are scheduled for IND applications in 2025. Presentations included&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.11pt">An oral presentation titled </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8220;ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">ine cancer models, with a favorable toxicology profile in non-human primates&#8221;</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.11pt">A poster presentation titled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8220;ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload, demonstrates compelling preclinical activity in hepatocellular carcinoma models&#8221;</font></div><div style="margin-bottom:3pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;We&#8217;re thrilled to have presented promising preclinical data at several key scientific conferences this year, including the ENA conference in October, and these presentations continue to underscore the breadth, diversity and strength of our platform,&#8221; stated Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. &#8220;Specifically, preclinical data on our NaPi2b- and glypican-3-targeting antibody-drug conjugates have demonstrated both potent and selective anti-tumor activity in multiple cancer models, with favorable toxicology profiles and robust tumor growth inhibition, highlighting the transformative potential of our approach utilizing our proprietary payload and antibody. We anticipate submitting INDs and non-U.S. applications in the first half of 2025 for ZW220, and in the second half of 2025 for ZW251.&#8221;  </font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:105%">Zanidatamab Continues to Progress with Promising Developments</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In September 2024, our partner Jazz announced new and updated presentations at the European Society of Medical Oncology (ESMO) Annual Congress 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">024 on zanidatamab highlighting its potential for the treatment of multiple HER2+ indications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">including HER2+ metastatic gastroesophageal adenocarcinoma (mGEA) and advanced&#47;metastatic colorectal cancer (mCRC). The presentations included&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.11pt">Efficacy and tolerability findings from an ongoing, open-label Phase 2 study (NCT03929666) evaluating zanidatamab in combination with chemotherapy as first-line treatment for patients with HER2-expressing metastatic GEA, which comprises gastric, esophageal and gastroesophageal junction adenocarcinomas. Data from 41 patients with HER2-positive metastatic GEA who were treated with zanidatamab in combination with physician</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8217;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">s choice of chemotherapy treatment demonstrated a median progression-free survival (mPFS) of 15.2 &#91;95% CI&#58; 9.5, 33.4&#93; months. After a median duration of follow-up of 41.5 (range, 23.0-52.7) months, the median overall survival was not mature, a Kaplan-Meier-estimated 24-month overall survival was 65% &#91;95% CI&#58; 48.0, 78.0&#93; and the 30-month overall survival was 59% &#91;95% CI&#58; 41.0, 73.0&#93;. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.11pt">A mini-oral presentation from another arm of the Phase 2, open-label trial (NCT03929666) that includes a cohort of patients with metastatic colorectal cancer treated with first-line zanidatamab plus chemotherapy &#177; bevacizumab (bev). In 11 response-evaluable patients, there were 10 confirmed partial responses and one patient with stable disease as a best response. The cORR was 91% (95% CI&#58; 58.7, 99.8) and median DoR was not reached (2.9+,16.7+ months). All patients experienced treatment related adverse events (TRAEs) &#8211; Grade 3-4 TRAEs occurred in five (38%) patients, three (23%) of whom experienced diarrhea. No patients discontinued zanidatamab due to a TRAE and there were no treatment-related deaths. Zanidatamab plus chemotherapy &#177; bev demonstrated encouraging anti-tumor activity with a generally manageable safety profile as first-line treatment for patients with HER2-positive metastatic colorectal cancer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#9702;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.11pt">A poster presentation on the trial design for the ongoing, global, Phase 3, randomized, open-label trial (NCT06282575) investigating the efficacy and safety of zanidatamab with cisplatin and gemcitabine (CisGem) versus CisGem alone &#177; a programmed cell death protein-1&#47;ligand 1 (PD-1&#47;L1) inhibitor (pembrolizumab or durvalumab at physician&#8217;s discretion if locally approved) as first-line treatment for patients with advanced HER2-positive BTC. The primary endpoint is PFS in patients with immunohistochemistry (IHC) 3+ tumors. Secondary&#47;exploratory endpoints include&#58; overall survival (IHC 3+ subgroup&#59; overall population), PFS (overall population), cORR, incidence and severity of adverse events and patient-reported outcomes. The study is currently recruiting patients.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:105%">Business Updates</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;padding-left:14.15pt">As of September&#160;30, 2024, Zymeworks has repurchased 1,818,530 shares of the Company&#8217;s common stock for a cost of $20.6 mi</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">llion, under the Repurchase Program announced in August 2024. As of October 31, 2024,  the Company has completed the initial $30 million of the Repurchase Progr</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">am for 2,545,402 shares at an average price per share of $11.79.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:105%;padding-left:14.15pt">On October 15, 2024, Hollings C. Renton submitted his resignation from Zymeworks&#8217; board of directors, including as chair and member of the board of directors&#8217; compensation committee, effective December 10, 2024 (the date of the Company&#8217;s 2024 Annual General Meeting of Stockholders). Mr. Renton&#8217;s resignation was not the result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices. </font></div><div style="margin-top:12pt"><font><br></font></div><div><font><br></font></div><div id="i6b7d61cbef94495dbca3cb508ca4facd_4"></div><div style="margin-top:18pt"><font><br></font></div><div style="margin-top:21pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Financial Results for the Nine Months Ended September&#160;30, 2024</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Revenue was $45.3 million for the nine months ended September&#160;30, 2024 compared to $59.1 million for the same period in 2023. Revenue for the nine months ended September&#160;30, 2024 included $32.8 million for development support and drug supply revenue from Jazz, $8.0 million of milestone revenue from BeiGene in relation to the acceptance by the CDE of the NMPA in China of the BLA for zanidatamab for 2L treatment of HER2-positive BTC, $2.5 million of milestone revenue from GSK in relation to the sequence pair nomination under the 2016 licensing agreement and $2.0 million from BeiGene and other partners for research support payments. Revenue for the same period in 2023 included $56.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">million for development support and drug supply revenue from Jazz and $2.8 million from BeiGene and our other partners for research support and other payments. The decrease in revenue from Jazz reflects the transfer of responsibility for certain clinical trials regarding zanidatamab to Jazz, with such future costs to be borne by Jazz instead of being incurred by us and reimbursed by Jazz.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Research and development expense was $97.6 million for the nine months ended September&#160;30, 2024 compared to $118.1 million for the same period in 2023. The decrease in research and development expense was primarily due to a decrease in expenses for zanidatamab, as a result of transfer of responsibility for this program to Jazz, and a decrease in expenses for ZW171 and ZW191. This decrease, compared to the same period in 2023, was partially offset by an increase in expenses for ZW220 and ZW251 and other preclinical and research activities. Stock-based compensation expense </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">increased primarily due to a lower expense in 2023 as a result of the cancellation and modification of awards in respect of employees transferred to Jazz.  </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">General and administrative expense was $45.3 million for the nine months ended September&#160;30, 2024 compared to $55.6 million for the same period in 2023. The decrease in general and administrative expense was primarily due to a decrease in external consulting expenses for information technology, legal fees, and other expenses for advisory services, insurance and depreciation and amortization expenses compared to the same period in 2023. This was partially offset by costs incurred due to the termination of our long-term facility lease in Seattle in 2024 and an increase in stock-based compensation expense over 2023, primarily due to reversal of compensation expense for options cancellations and modifications in 2023. </font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">During the nine months ended September&#160;30, 2024, we recorded a non-cash impairment charge of $17.3 million as a result of our decision to discontinue the zanidatamab zovodotin clinical development program which utilized the technology represented by acquired in-process research and development assets.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income, net was $16.1 million for the nine months ended September 30, 2024 compared to $14.6 million for the same period in 2023. The increase was primarily driven by an increase in the average interest yields of these investments during the period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Income tax expense decreased by $3.8 million for the nine months ended September&#160;30, 2024 compared to the same period in 2023, primarily due to a reduction in U.S. taxes under the global intangible low-taxed income rules and Subpart F income rules for the nine months ended September&#160;30, 2024.</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss for the nine months ended September&#160;30, 2024 was $99.2 million compared to $104.2 million loss for the same period in 2023. The decrease in net loss was primarily due to lower research and development and general and administrative expenses, as well as a decrease in income tax expense, which was partially offset by a decrease in revenue and an impairment charge recognized in 2024, related to zanidatamab zovodotin. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of September&#160;30, 2024, we had $374.9 million of cash resources consisting of cash, cash equivalents and marketable securities, comprised of $122.4 million in cash and cash equivalents and $252.5 million in marketable securities. Based on current operating plans and assuming receipt of certain anticipated regulatory milestones, we expect our existing cash resources as of September&#160;30, 2024, when combined with such anticipated milestone payments, will enable us to fund planned operations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> into the second half of 2027.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Zymeworks Inc. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks&#8217; mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company&#8217;s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company&#8217;s proprietary Azymetric&#8482; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting. In addition to Zymeworks&#8217; wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow &#64;ZymeworksInc on X.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Cautionary Note Regarding Forward-Looking Statements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This press release includes &#8220;forward-looking statements&#8221; or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks&#8217; expectations regarding implementation of its strategic priorities&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> the anticipated benefits of the collaboration agreements with Jazz and BeiGene, including Zymeworks&#8217; ability to receive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> any future milestone payments and royalties thereunder&#59; the potential addressable market of zanidatamab&#59; the timing of and results of interactions with regulators&#59; Zymeworks&#8217; clinical development of its product candidates and enrollment in its clinical trials&#59; the timing and status of ongoing and future studies and the related data&#59; anticipated preclinical and clinical data presentations&#59; expectations regarding future regulatory filings and approvals and the timing thereof&#59; the timing of and results of interactions with regulators&#59; potential safety profile and therapeutic effects of zanidatamab and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Zymeworks&#8217;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> other product candidates&#59; expected financial performance and future financial position&#59; the commercial potential of technology platforms and product candidates&#59; Zymeworks&#8217; ability to satisfy potential regulatory and commercial milestones with existing and future partners&#59; the timing and status of ongoing and future studies and the release of data&#59; anticipated continued receipt of revenue from existing and future partners&#59; Zymeworks&#8217; early-stage pipeline&#59; anticipated sufficiency of existing cash reso</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">urces and certain anticipated regulatory milestone payments to fund Zymeworks&#8217; planned operations into the second half of 2027&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Zymeworks&#8217; ability to execute new collaborations and partnerships and other information that is not historical information. When used herein, words such as &#8220;plan&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;may&#8221;, &#8220;continue&#8221;, &#8220;anticipate&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, &#8220;progress&#8221;, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks&#8217; current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation&#58; any of Zymeworks&#8217; or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">its partners&#8217; product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable&#59; Zymeworks may not achieve milestones or receive additional payments under its collaborations&#59; regulatory agencies may impose additional requirements or delay the initiation of clinical trials&#59; the impact of new or changing laws and regulations&#59; market conditions&#59; the impact of pandemics and other health crises on Zymeworks&#8217; business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#8217; behalf&#59; clinical trials may not demonstrate safety and efficacy of any of Zymeworks&#8217; or its collaborators&#8217; product candidates&#59; Zymeworks&#8217; assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect&#59; inability to maintain or enter into new partnerships or strategic collaborations&#59; and the factors described under &#8220;Risk Factors&#8221; in Zymeworks&#8217; quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedar.com). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ZYMEWORKS INC. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Interim Consolidated Statements of Loss and Comprehensive Loss </font></div><div style="margin-bottom:15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Expressed in thousands of U.S. dollars except share and per share data) (unaudited)</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development collaborations</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,506&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,273&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,086&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,353&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,775&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,558&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,095&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,852&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,968&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,623&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment on acquired in-process research and development assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,287&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,205&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,743&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,166&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,718&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,205)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,237)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,893)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114,632)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,660&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,073&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,594&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,624)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,577)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,820)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,038)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,110)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,154)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,850)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,687)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,189)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104,192)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss)&#58;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized income (loss) on available for sale securities, net of tax of nil</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,639)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive income (loss)</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,905&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(485)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,639)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,945)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,172)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,585)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,831)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.30)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.53)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.53)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common stock outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,128,531&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,575,773&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,244,893&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,212,756&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,157,101&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,575,773&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,266,177&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,214,482&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZYMEWORKS INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheet</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Expressed in thousands of U.S. dollars) (unaudited)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.333%"><tr><td style="width:1.0%"></td><td style="width:68.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.499%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and short-term marketable securities </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374,327&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,704&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,477&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,865&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,122&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,667&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,930&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,716&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,024&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,152&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,880&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,707&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,992&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,202&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,771&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,265&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,311&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,174&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,074&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,978&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,806&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,152&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,880&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Investor Inquiries&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Shrinal Inamdar</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Director, Investor Relations</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(604) 678-1388&#8239;</font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ir&#64;zymeworks.com</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Media Inquiries&#58;&#8239;&#8239; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Diana Papove</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Senior Director, Corporate Communications</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">(604) 678-1388&#8239;&#8239; </font></div><div><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">media&#64;zymeworks.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zyme-20241031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:457b11c3-c8ff-41d3-9bb5-ed20e848ffe8,g:a9be2a4a-fbbc-4261-b028-b0c2d94038e1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zyme="http://www.zymeworks.com/20241031" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.zymeworks.com/20241031">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20241031_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20241031_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.zymeworks.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>zyme-20241031_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:457b11c3-c8ff-41d3-9bb5-ed20e848ffe8,g:a9be2a4a-fbbc-4261-b028-b0c2d94038e1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_122c31a6-5c4d-4281-bfae-840fe21383fd_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d18bc38c-2c8d-4ed0-8ad9-39dfad324c9d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4ff1376a-0a56-4070-a180-bc74c2990959_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_21200b38-b4f1-413e-aac7-0f9271cc9fde_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_59ef1b20-bb4d-407f-9a39-43f89c5dbd80_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_f2ccf460-aab1-4588-85de-5c050cd7f770_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5f29f2ef-0cca-46cb-9e0a-8b1cb8b2d867_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_46c2c511-85e0-4036-862a-115903339d94_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_366e67b3-62ec-47cf-9e1d-a2dfe13bcfa8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b6135bb4-a99d-4175-b1b6-6779f5aa5cd2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_240767e1-c69d-4fea-b254-04278213d3d9_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ca07125d-e622-4ca3-8aa7-ed1140ba07bc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9aacb445-2936-451c-8eae-52bc97af7eeb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0dec6fd0-429a-42bf-983f-d0edb4494f43_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2b3ba02d-4574-422f-a772-232565b2669c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7ed11cc8-e1c6-4b26-8a78-c3cc8f9ae1c4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_aa000ad9-b60d-4567-9be0-a83d164952df_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_006ac956-f346-4304-a95c-23d4a2fb2415_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_19f38f23-6ad2-4943-a723-306e9b0396d9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_b791743e-d46e-4373-93b6-441361d6427e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e183a7bc-e505-4cf4-a48e-fc6af5d7a464_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_63f82954-b819-4203-93d6-5f81091fb920_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>zyme-20241031_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:457b11c3-c8ff-41d3-9bb5-ed20e848ffe8,g:a9be2a4a-fbbc-4261-b028-b0c2d94038e1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zymeworks.com/role/Cover" xlink:type="simple" xlink:href="zyme-20241031.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.zymeworks.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a9f427a1-59f0-4565-949e-1e442bc7e299" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_DocumentType_a9f427a1-59f0-4565-949e-1e442bc7e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c2d96345-193d-4a13-b49e-40ec56257e97" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_DocumentPeriodEndDate_c2d96345-193d-4a13-b49e-40ec56257e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ef17faca-b83c-442b-8146-1cdc5605cb32" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityRegistrantName_ef17faca-b83c-442b-8146-1cdc5605cb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_482de1ef-66dc-41db-96b3-c5e0fa0da4f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_482de1ef-66dc-41db-96b3-c5e0fa0da4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_37badc40-b6d7-49d6-ad8f-057c18c967eb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityFileNumber_37badc40-b6d7-49d6-ad8f-057c18c967eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_05b3f9d9-8eeb-4856-a969-a70336a35050" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityTaxIdentificationNumber_05b3f9d9-8eeb-4856-a969-a70336a35050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e837b5d7-8c37-46b3-b85e-c49ac43dc198" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityAddressAddressLine1_e837b5d7-8c37-46b3-b85e-c49ac43dc198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_62a99df5-36e6-47bb-b3a8-a1361bd849b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityAddressCityOrTown_62a99df5-36e6-47bb-b3a8-a1361bd849b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_075ebf51-566f-46e5-b9fa-df8df600dc98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityAddressStateOrProvince_075ebf51-566f-46e5-b9fa-df8df600dc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3aeb7c31-771c-4b12-b464-b5171eaef691" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityAddressPostalZipCode_3aeb7c31-771c-4b12-b464-b5171eaef691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7978931f-958e-4ead-b5e1-84966392f3ce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_CityAreaCode_7978931f-958e-4ead-b5e1-84966392f3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8e5fc73f-d3df-4b69-915e-d6a2e3fe2360" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_LocalPhoneNumber_8e5fc73f-d3df-4b69-915e-d6a2e3fe2360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_6fc39d32-3168-40b1-b188-10b2fd2d0627" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_WrittenCommunications_6fc39d32-3168-40b1-b188-10b2fd2d0627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c0690fe0-ca48-4898-8ff6-19be139b63ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_SolicitingMaterial_c0690fe0-ca48-4898-8ff6-19be139b63ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_82fef77c-b842-4cba-bd3a-d87424771a8c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_PreCommencementTenderOffer_82fef77c-b842-4cba-bd3a-d87424771a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_b24322ae-194b-4960-9a5f-74f1e9202a5a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_b24322ae-194b-4960-9a5f-74f1e9202a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a6fa749c-f75e-4122-b544-6def871ca93f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_Security12bTitle_a6fa749c-f75e-4122-b544-6def871ca93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9dd00ca8-cc42-45bd-9582-13948ebfb563" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_TradingSymbol_9dd00ca8-cc42-45bd-9582-13948ebfb563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_aac2dc5a-3549-4d9f-a3c9-7f0cffaccff3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_SecurityExchangeName_aac2dc5a-3549-4d9f-a3c9-7f0cffaccff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_af8082ff-c61b-4dfd-b798-4b4869864df9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityEmergingGrowthCompany_af8082ff-c61b-4dfd-b798-4b4869864df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_404c5f93-ea40-4b06-ae1f-773c023d64c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_AmendmentFlag_404c5f93-ea40-4b06-ae1f-773c023d64c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3fc37c27-d201-4819-9201-8ea3ad78e56a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f6764cc-4114-4c12-894c-1b73b1cc1bc7" xlink:to="loc_dei_EntityCentralIndexKey_3fc37c27-d201-4819-9201-8ea3ad78e56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>zw_logo.jpg
<TEXT>
begin 644 zw_logo.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0!,17AI9@  34T *@    @  8=I  0
M   !    &@       Z !  ,    !__\  * "  0    !   !<J #  0    !
M    G     #_[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0        X0DE-!"4
M     !#4'8S9CP"R!.F "9CL^$)^_^(-7$E#0U]04D]&24Q%  $!   -3&%P
M<&P"$   ;6YT<E)'0B!865H@!^8 "  #  < ,P 286-S<$%04$P     05!0
M3                        /;6  $     TRUA<'!L
M                                               29&5S8P   5P
M  !B9'-C;0   <    'N8W!R=    [     C=W1P=    ]0    4<EA96@
M ^@    49UA96@   _P    48EA96@  !!     4<E120P  !"0   @,86%R
M9P  ##     @=F-G=   #%     P;F1I;@  #(     ^8VAA9   #,     L
M;6UO9   #.P    H=F-G<   #10    X8E120P  !"0   @,9U120P  !"0
M  @,86%B9P  ##     @86%G9P  ##     @9&5S8P         (1&ES<&QA
M>0
M                                                 &UL=6,
M    )@    QH<DA2    %@   =AK;TM2    %@   =AN8DY/    %@   =AI
M9       %@   =AH=4A5    %@   =AC<T-:    %@   =AD841+    %@
M =AN;$Y,    %@   =AF:49)    %@   =AI=$E4    %@   =AE<T53
M%@   =AR;U)/    %@   =AF<D-!    %@   =AA<@      %@   =AU:U5!
M    %@   =AH94E,    %@   =AZ:%17    %@   =AV:59.    %@   =AS
M:U-+    %@   =AZ:$-.    %@   =AR=5)5    %@   =AE;D="    %@
M =AF<D92    %@   =AM<P      %@   =AH:4E.    %@   =AT:%1(
M%@   =AC8453    %@   =AE;D%5    %@   =AE<UA,    %@   =AD941%
M    %@   =AE;E53    %@   =AP=$)2    %@   =AP;%!,    %@   =AE
M;$=2    %@   =AS=E-%    %@   =AT<E12    %@   =AP=%!4    %@
M =AJ84I0    %@   =@ 1 !% $P 3  @ %  ,@ T #$ . !$  !T97AT
M $-O<'ER:6=H="!!<'!L92!);F,N+" R,#(R  !865H@        \]@  0
M  $6"%A96B        !O#   -N8   #"6%E:(        &'D  "X?@  %')8
M65H@        )>8  !"<  "]^6-U<G8        $      4 "@ / !0 &0 >
M ", *  M #( -@ [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L
MD "5 )H GP"C *@ K0"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$!
M 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!
MF@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4
M ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#
M0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15
M!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%
MI@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9
M!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(
MT@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN
M"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,
MV0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E
M#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1
MR1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+
M%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7
MKA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL
M&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>
ME!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5
M(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<F
MAR:W)N@G&"=))WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/
M*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHO
MD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E
M-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\Y
MO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A
M/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%
M$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,
M2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1
MFU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O
M6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?
M85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:2
M9NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N
M:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^
M=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^
MPG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[
MAY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0
M;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0
MF?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C
M=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$
MK;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBW
MX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?
MPMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-
MM<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CH
MV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D
M_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E
M\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]
MNOY+_MS_;?__<&%R80       P    )F9@  \J<   U9   3T   "EMV8V=T
M          $  0         !     0         !     0         !  !N
M9&EN         #8  *F   !4@   3<   )U    F0   #\   %!   !40  "
M,S,  C,S  (S,P          <V8S,@       0NW   %EO__\U<   <I  #]
MU___^[?___VF   #V@  P/9M;6]D        $*P  -#!,$%65-C_M8
M                =F-G<        P    )F9@ #     F9F  ,    "9F8
M   ",S,T      (S,S0      C,S- #_P  1" "< 7(# 2(  A$! Q$!_\0
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M# P,# P,# P,# P,# P,# P,# P,# P,# P,_]T !  8_]H # ,!  (1 Q$
M/P#^_BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /_0_OXHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHK)UC5]-\/Z7/K6L3+;VMLA>65S@*!W-*4E!-MZ :U%?E?\ $/\
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MDDGMG&*_?CQA^P7^SMXOUI]<ET@6DDK;G$)(!/Y_RKWOX8?!7X:_![3/[.\
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M%?#B3"QE,6\L<G'XUQ'_  ]DO_\ H68_^^F_^*K\]K>*7#M*HZ<J[NM/A?\
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M-U?Q'':N4:ZTZ+,1(.#@MMJ\-D>.Q"3I4FTU?Y$XC.L'0;56JE;0_8BOE/\
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MK\2[_P#X+D?LYVLYAM/"_B*[0=)(H5P?<9--L_\ @N5^SG<3".^\+^(K./\
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M;_P3T^&?A;]KS]O/XF_%_P".=NNOW&@WLMO:Q70W*IC<(CX/H@VU_2U#\-O
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46538451121152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zymeworks Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-3099146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Patriot Drive, Suite A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middletown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-8744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZYME<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@/M+I>Q[PVU;RW\=QO\#4$L#!!0    ( &*!7UF?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( &*!7UD'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 8H%?69:CR*ON    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 8H%?69E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !B@5]9<G\7;T<$  "!$   &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 8H%?69^@&_"Q @  X@P   T              ( !B@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !B@5]9EXJ[',     3 @  "P
M@ %F#P  7W)E;',O+G)E;'-02P$"% ,4    " !B@5]9JL0B%C,!   B @
M#P              @ %/$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M8H%?620>FZ*M    ^ $  !H              ( !KQ$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 8H%?6660>9(9 0  SP,  !,
M             ( !E!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  WA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zyme-20241031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zymeworks.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="zyme-20241031.htm">zyme-20241031.htm</File>
    <File>zyme-20241031.xsd</File>
    <File>zyme-20241031_lab.xml</File>
    <File>zyme-20241031_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zyme-20241031.htm": {
   "nsprefix": "zyme",
   "nsuri": "http://www.zymeworks.com/20241031",
   "dts": {
    "inline": {
     "local": [
      "zyme-20241031.htm"
     ]
    },
    "schema": {
     "local": [
      "zyme-20241031.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "zyme-20241031_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zyme-20241031_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.zymeworks.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zyme-20241031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zyme-20241031.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.zymeworks.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001937653-24-000049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001937653-24-000049-xbrl.zip
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M?Z<\@KV44N0W-^"!#73./HDX]>!'*Z>Q"9<MN.. R&IY8IJ\[@Y@5G1V;N#
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M6Q+C*P"<;[C:J$7D^N5M(N>G3*A==VCXP2T[G&N,UA1W($ZC2Q?#%@<??[L
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MP;>]D774^(!O\0'O5I+D$J*]E#%(30D)Q.%-,0*OJ\(;&G3D6"7U9I=KO4W
M(#U0_Y0E)Y47GIWC"<.7;]656P?XJT.# 6<%TG>(C1[$-]L#>L/FISA9$AB:
M,98%DU@N<,Q8!GUS$290$Z8I5G.4TG!EW%#W,71*'3"61*N.7Q*LSJO"L3('
MVQ7;'F"BK8I)LP:VQ^R-*_N0Q[ W-IFGQ3O@#MZ\/3[4,IO,Q-_"4/*TO"^N
M8 G@SW\[A9_'0M"U=9C,@$6W)$'TU6W+N0JTIJ6Y ]IWPS3VKENJA K3*M$Z
ML0DS&GEFN<H2-Y;:))>3':JNAX.5?3XY+%S$1XD72EP156#7%;"I*/7Z$TQ(
M7-%VO3VFA^@>K?*3,MB-/\QR-V2+3?R"=NM,50WC3IV<GAUFB1VZ@Z!N7?!1
M]OR+5_874T .LQR0-CN?9MGU1KF*0%]EEW<4*<O:?,OC0FN8;+3LRCJE$V6W
M$GGA'+ZXA 7P:B(G.PYU@ZD0B]+UI15=Y"<:[[NE:B]E22QDM;8K6]92.YG;
MKX.JN(.P>#FJ:D6:M[>G_DYR4V)IJ&9=%&018.;A5-W[\?Z0PC6,:>#C[5'J
MW$#E@3PJ-N%UJX.MU*(Q"*^J6KE2H1\F9.ILFQ5(<T5-Z%E(3>CU'ANTB]5P
M@KKS$+5.TX@@BKX;"Y4YV!2S.<LNA<O2-^;N0LD/)8\ ;"U*@E7A.Q)TORT%
M77@9X!KLT@5^9%=75^WO67LBF\HT'55&S'[Z8= [RAX!2(S$\?_K=;MG=?K?
M"4^)AT',O <!#1)#IYK\)F\^:[T-0Y**=)=E=7N:^C7C^BP3"Z0?7T>35%6L
MZBRE;G9K>6I]<;8^W8%HB3#4G8&R&)Q@N):#JAM2V2V $3LWEM&B8I[PA;K4
MR1H>Z^<O\H>.9;#7''>[,IG")_>;-#"R1\VSBD?/OMES+&$OC-$KCM'.CG1U
MR5)<KMLS>1FH9/TDO_XS-(HC**GC47/C"N:7W@LEHO*,)C<S*K3%A.*@P-12
MERW? E07!X.^O%F4?"@30'537(>.^(.8 +FBM.$R*ER]>S6GEI5MY+E)1(ZD
MR\K[FI]LY6@DJZRS5<>1ZF]VS3TB4"HD)D>]+#)+2A?H@N9 VB,NDGZVI0K#
M_*'$]17WJ60;RENFBT@!M\CK<M7>9MXT23ZK^UD91%146*'Z\86RE;BO+IK%
M'RX!WI69RI9Y/$EIEOK6*VDLT]YIE:L[/&2UU;!T?3M23E[+Z4;EGGBE[CWR
MX36\IUY>\#A.75DD00Y+!7WS6:G5T#F&TP<YC_S\EXNYE^YME141\7+5:?&F
MU5K)A&5"VRF7ZBRU97(N4@=BYZP6 " M*3Z-:A6E%'Z@_ DY$>1&9KDE8>4%
MIK*C??5T;A)YF)T13Z\+;R@0;]G4+7C/)>EE/O/"@C1D?!".)96)53Z53)NW
M6R@$ $KYPK=/<%6I%FY0UH!Z]=5QBLX_M%&H&G<U>%!+#E(1#3S4#<,DN>+1
M$8J5#5L-6=P8'5B+.9Z,=6_B!D'7I\O+SDH00Y=8%^RAW,M;RC!3=PTAKJ-:
M\XCT2.$G;?8%@T9TO0S*?1? +,S'B57D*,/3N+,*.6=7CJO[AY<_E@)G^5.?
M7R]_I'EF^?.<$):_R03#\A<8PEKYL6HXE7U.7 \" 'L4YU?UQ 1]49=1)!PV
M'LO<$W=ZS=8;$25KV""<5 #+RXE^$CMCHC0=:ZZM#7F'\Q3KXC"4B$D1X9_2
M#H!_9-<>X1<%F1WJD@8,,V,0(%(A"1)G2K:H:GPL/' C._5C*N I%S7"M FQ
M>=>RQC%._85Z-V[*TOIE(YSUFT+/2.])NH!UKZ(Q%4 M 18\%>SS'J9Q<09%
M9XXB-(4Q99P'W1ZAC%G"*UV57IG$JX-G6SR1=WI?JP.?"^7SQ-IG$D'%=P*]
MZL9 Y%=='EKUO$UB/7[V!+FJ@&,CK 9MH[V6RAY'A)ML<H%)MRS63XI(YABH
M:UA#RL2)[<B=R&O6T()R991'%H'<L/WEM#N]J5.^7,TJBTK0$4+6'E>J?G1$
M%($7RRR?'$RDB5W4XL9[LEPRV*#4WJHE@\0XY:Y',8!B*#.G:S(OX4^5'%F$
M6MHVD!YLCF$!O :>7TL!B>Y^[&YR1>R8L10.FR,TH.E+%_ES"=QD,^#VG*ZO
M+R Y\E7+>6GABH!3ZWV9!D8F64D?RC<4%S #-.2J;0 .0JXJ#*C6G EK6EJA
M<X'V5:PU_&3LE0+ <*HA">* FEQY_$K76<U4!Q7UG+)Z$82XA8_+PRW@4>'K
M"_"DD)^#!,+F.[*C9I5<G:A6(T8Y6:HZ@S9+60$L3(@R7K;KBN7:N;+0DZRR
MB>4=;D;A6$C@J$O\*,*!5VYA2TX<@]*NH^JE" 1H<FN6 TV:< H=QHH7XF5=
MC%0%^QHY5B:?\"8N6F>QY%I*OEAU@2PYOK#4.K.GLD,W*FRM)6,L[RDI 7P:
M@/323(@9:Z17Y-1@D!PO^ARS(O$VYD@&+//K?DM8$:_<RQQP58RDC1ZE. KZ
M2#*@PE>?W/@K^XUG'0_0J>I6'.E_4G@[8@R5)Q=(=;B@^Q?1&^#D_04*#D_\
M<>;T/,%,#9DQ<6"'"U=F0LA</;4UX007C[$RZ<X'O-^>A9<TCORWPR-T[1]6
M9+34S\=][*&&GLVK81#>(G$;&B#?CP9)N@DCWOLUH59_2,6R>(0$."6!2>@B
M2TLS '-.B==("/&<P N!'(_#DT /*1G'+E?W@]T$F3'M!&@-A7L1:8)<^RJ/
M.P-BD@"42A'?YCR-$4S<Z./&G_O879%GCEEJHR'=63B^@:%TL< <?TTTF?8#
M> 6BN]@IB&@]X5\%VD] 79ZZ*)>NT:"63@9U$H(O,&]1A5E1T00W60[2M4M5
MP\2:!4/!N!6ZAU'Q<>H()QM(TJ4AL,HT*%K1<IRFR>$&62>/DG/7V2CG[H]_
MOSO[\N'3/R_8^?N3M;+I"6=%R8LG(?8F0EON''6)Z^,5!72!)I'61<':G;*W
M&+ZF.#QFY(HYME8 -J>/-\UF[N_B &BI!V?2&:#OW :C"=9""Z,$ P=U9!1K
MZ2';0)$+)FL*A4[!0W8 [ =@"?;G<,-5CVG1*N=8LU<$@J=%BGD1B]?Z+T<.
M=5^\?NT&M 1ZZ*@\'.SAT:6(* K> KMU%KRF/E/RZYQ3VAW)+0FP2.+H-ZNO
MV_35SXFS^EUOV!X.AFN_[K3-M=_=-*QIMKO]\9V&O?F[7N\1)MMI#XEO'W:R
M5MNR'F6RW='HP2<+KQSW'GRRX_:X,]AHU)^)<"7Q G_$8#;]_57WU5+SVM<=
M)CLOZ?&RGXY7?FHMON&/95LVR3GR*N)E?I*L]-"2:G1K2\D.Y3U@,^CJIDU8
MN)<)G>7U/O^MN:&=U<K.W)=Z\I\J64T  C4#W2^MU[I7^U?J]'7/!;^TC>L^
M!-\]T[UIB.I!B.H6D;4:S;5M(:;3FU:-7357P&*X>'0,OMKJLY/W[-N$6M:M
M]<'(Z+;-O,\8S21W-\FMF4BE1"PQ$:,_Q^UAOZ8,975NZEI6]O@N,]PV>]%A
M&XJ5QQ&E&TJ6'^^UQ.+2J/RF5FLS!P:\0-8!WV>9FJJW6.Y6++OTRF6V;XAN
MSXBNWQDT1-<0W1.NK=<WK&&W(;J&Z)YP;?VQT1GM4-(]>ZOO0]9)17?K*5]#
MO"/3HAGCB<9X*199YR:+;"VU6]MM1*6^J)]0[0Z,;G__-?ES/R7+& [[S2G5
M^Y3&0Z/?'S6G5.]3,LV1T1GOD)D>"$?NAYI=WW?\3HJV8BOVA>RZQJAO;4EU
M-YS\8PF'34'F,SVE@3$>;"O"FU-Z>O=3US*;4ZKW*?7[QL#:UK1XP%-Z('-V
M,]VZ[K)V<T0*>D='<)[W0,9>*-MWWE]*V7X9")%*9:RC!L@WQ]0<T_TAU="P
M1L/FE.I]2CMGIF<?7?D<)MBD9R7&<A\[>&W6U3Z28+]C6)UM_3);;<0>X?UG
M=;*]L3'LW=$2:$ZVSB<+)VJ8@VV#\LW1[L/1#KO&T+RC+^QQC_9)+?M=[#V5
MZE(/HM7K7NX"2)\581YT>P@4#K=%J?40-P]H9CRS4^T:5G?8G.KS.E73[!FC
M<;<YUN=WK(.N5;-C?=C(>IT!PLK]LB\LFMXS^J,F %CS0^H;@\&VY5#-(>V@
M:&WK4H[FE)[ZE$#@C7LO)):^,XM[(J9A) H7$=_1._\L(9\U-@96KV:(KP'R
M]SW5H=$?-E;W,SO5\<@869WF5)_7J<(?1J<[JMFQO@BCFYIXG&>X0 ?O7YC5
M?6!9@\VIKS$2GEQ &*:YA=1O#NC)8QR#<7,\]3V>GF'VM[!P&OMZ\[U]+Q+F
M@8W].-CEF3;GV'#Q-><J:VR,^L_4&&G(]_F3[\@8C)ZIAZ0AWV=/ON.Q88ZV
M0)T-^3;D6Y]5'Y@= .7C9YIHLG%IZ6[\73+)Q"Y=(J-B8P>(Y0_+[<&J2T3W
MO2E6,\:C- F[;U7U+DJJB2G^%:@[:)TR+U"!]25W/;H]".]4C+E']URK*_0H
M38ON0N/?Z*Y*UWN1U=6F,=ZZRJN:AO8E"K6'AW30&VV?8-\<SU,=SZ"S;2Y0
M<T1/'XP9=+>WNQITNJDB5O74MV'4>^C89UG5=P?MVY1K[L'!;J>QFR/=@R/=
M7LLWQ[H'Q[HM,FA*JA]BU\MW(3>AZ!?I3;:&QKCW3"O'&_)]_N0[-LQAW6(A
M#?DVY+MQ54+_#F[%AGP;\JW!J@_,3M\8=<V:T:\"[GH6>LJRY_ .@H:%U79A
M24Z88CRLM-Q=QS6;*>YBBL_9PK2**<YL(3W2?ABP>,XC<?=;U#8-H31CU&>,
M%W6]RQL>N_9]"B:>&^*I6F+-<4VG?0=O9(T<R0VY[1FY];; T VY->1V/ZNM
MW=WKDMB&W/:,W/I;-+NL7P7I?L#.4]=+$^'<Z[+S9\8K54NL.:]L!SSKE\'8
MD-N>D=LVP+,AMX;<GA!X-N36D-L3 L\')+?G?'$7^?6_T#^$T^(P)3X3F6\_
M">VO+$R3..$!+N7N?OY]*/QKQGB4>-9^&%R5?OYLU<^S@F<X,$QK9/2[VS::
MKY\N?^XGU3'ZP[XQW+J/>7-23\]35H]NA&E.JMXG-1@9EFD9P_ZVE_O5#UKN
MAXI=X]/<B,SVM^<B*MG^T# [S6TN=3^INRK9YJ1VH&0'P%?#;6]=;TYJ%TJV
M9_1&UHZO=ODYP;8UNDJ^T'9'37=HP7H68>SB5:2O(^'QQ+T41U>ND\S56HI/
MR3>\[N2/\$D<HGY;>41N_*^_3' 6:O6R5+_P_WF6W[S@,]&:1()_;?%I(J+7
MW+OBUW'Y];X;Y/L\@IEO^=+B4#R:P6B4O&T]0=.A8:4+ZH]_OSO[\N'3/R_8
M^?N3=GG*3]" H7I2)V'@8!-\A\'?**N= WYA;[C' UNPB[DH7$NW9E\5H8QW
MMK,'9]\6D8AC:N?$DGF8PFA.C V:_M6^:#,G]#P>Q8?L( UXZKBPPL,=+LK:
MR&-9%B;$VCEG4M:VC<M:Q.*U_LN1X\8+CU^_=@,:CQXZ*B\(X?,R7$91([]6
M3#8>M[O=+O*9 N[JQ8H%V\2"2_)-?C<8M?O=]5]WVN;:[VX:UNRV>^/AG8:]
M^;OQL/<XDQUO.FR%AM7'&(2!N$>)R!9>TYW_](8E/^!$*O"$+0+00$\#*,:W
M23/2;1=BD0A_(B+6[1BHW:R.U=L@(O%<]^-4V&H[3+T=W0VVX^F9:&V-6&>[
MBI\=O/(.[+=/,<%JPCH&Q)"LOQQPWV-;CWC2U>[!.ISTFKXA:12!7&.<3OPE
MEG+MG,'7=H%]"H-L#57P>&XP&_[/Q']2]Y)[0",Q ].!Q?,P2EJ@"'T&\/FK
M4/ [ZP/+JCO2W=N[L<?I-ON7YVV-AX;5V?_+K1NJVR>JZPY[1M>JG5?W$7&!
M)+ENG0'"L6W#.D#X1V!L@"8 :?_"$F6LKC%L&A+7_93,L=';.B+TZ*?TB.!R
M#V2'NF&C9&*\L 0 RS)&@SMV)*X1D'KFIP3"P[1V&*2LJ4-B%\W/Z3S>AF $
M;VUC/G,--QP:@T'M-%R#0\JG-#*-<7=;RWF?<4C=X8>7R9(7"4 &?6-H;IOD
MV@"0IY8: Z-CW;$=?LVEQKY%1.3%*]6RXK9%-FU0][T-:F\T-,S^MJ; 5CM0
M\\+GAH;WG8;[HXXQ&MT1@^Z"AA\H(:56_6#W=HK/7.E7)[R\=?G$]<BYT*0_
M/'_+4&>]>/FQO\3N!DUDDR*;"WY-#D9,;^&V':7"8>+; I/_M[8 7@!&VB<D
M9!K#SOZ[3!NBVR>BZ_6-\?B.%F3-?3G/)!+M;8#VGJ>?L6L95J=V@<[&&UP^
MI;$Q'-:N8< SMPMO"T3?5V;L;T2SB_7VVZ:PU ]$/?-3&G2,KEF[5EXOTKL@
M(T@/!#*>U=W0IM4QS&%S[?=S/%IS8'3VZ6AWCF=VEEUW@9U=YZ$'6Q[_],/(
M,H='5.:57+_(O+KN8&",AZ.ZJ<X&X"RY508]8]398;N^FB*<G8F1%9@CZT.W
M%"X;J@;5HV4YKODRDQ4><FMJSO1W2L=YP/VI>0%KPQTOF3ONENA36^Y8JTI7
MVO?MYJ:$I;*36]OH533@N^,S]_ONR?=I=:,VV9"7VHOQH0_)W+2]8<+MY98O
MNR"JY?FN$)79A_F>!Y<"L&7$S@- D]%*QLYN9W<QC]P T/!YP'V'1[N?E25[
M;D?"ACTS6+9[GXB?PB"NR10/!IW>(1L,1RVS.QJAP= =;WJH_4'7-A]Q;F[T
MTP^#WM'W:U]<A='7N&V'?FU%\V9T^DXX+E]B(;7IZH]ULONI9WKJ\H"SCWP1
M7HJ:3.E"!"ZP4,Y5)V&T"".>"/B;[Z<!X)V:\!;-MY*WMCSF1^0QFJ./!'E/
M-JL7@/AY$CK7\,<\\;U?_Q=02P,$%     @ 8H%?64_=<U/C$0  09H  !$
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MG@<BQL2+8U-[@$WU(38.8O.EV[ENGY+>]<EUNT<6N7H.^DT!M]=N?;GJ7'<
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M$VF/ ?X(ANW!4@(B$84"6$_*1NHQL,"',X M#;!)3H!:HVFY[N+0Z'A(2<%
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MMHPR6$I#(UM$<F'S89@D, F5AJ$,PD"JV,3Q8)D= CNRY"P\E U\L'8 K#T
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M**C24!1#)G0 >4(4BB@+L3)NVR$]2-/LB%APT$;W/*31%Z_#HGJQ*+B)S#L
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M2P$"% ,4    " !B@5]9LSH(/ET"  #\!@  $0              @ &G0@
M>GEM92TR,#(T,3 S,2YX<V102P$"% ,4    " !B@5]9WF(,D H*  !]5
M%0              @ $S10  >GEM92TR,#(T,3 S,5]L86(N>&UL4$L! A0#
M%     @ 8H%?67NY#O.G!@  X#   !4              ( !<$\  'IY;64M
F,C R-#$P,S%?<')E+GAM;%!+!08     !0 % % !  !*5@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>zyme-20241031_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zyme-20241031.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-23">0001937653</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-10-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Zymeworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-41535</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">88-3099146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">108 Patriot Drive, Suite A</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Middletown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">19709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">274-8744</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ZYME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-21">2024-10-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-22">2024-10-31</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
